{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:35:26Z","timestamp":1794951326401,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02521-7","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:23:19Z","timestamp":1743816199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer"],"prefix":"10.1186","volume":"30","author":[{"given":"Kaichen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haosen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"3","key":"2521_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2521_CR2","first-page":"11892","volume":"31","author":"SC Ghagane","year":"2024","unstructured":"Ghagane SC, Rangrez S, Nerli R, Thakur ML, Gomella LG. Use of TP4303 to identify prostate cancer cells in voided urine samples. Can J Urol. 2024;31(3):11892\u20136.","journal-title":"Can J Urol"},{"issue":"suppl8","key":"2521_CR3","doi-asserted-by":"crossref","first-page":"viii25","DOI":"10.1093\/annonc\/mdx448","volume":"28","author":"AH Brand","year":"2017","unstructured":"Brand AH, DiSilvestro PA, Sehouli J, Berek JS. Cytoreductive surgery for ovarian cancer: quality assessment. Ann Oncol. 2017;28(suppl8):viii25-29.","journal-title":"Ann Oncol"},{"issue":"3","key":"2521_CR4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.euo.2018.08.002","volume":"2","author":"F Massari","year":"2019","unstructured":"Massari F, Di Nunno V, Santoni M. Re: Arnaud M\u00e9jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417-27: CARMENA trial: is this the end of cytoreductive nephrectomy in patients with clear-cell renal cell carcinoma? Eur Urol Oncol. 2019;2(3):340\u20131.","journal-title":"Eur Urol Oncol."},{"issue":"9","key":"2521_CR5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","volume":"55","author":"CL Stewart","year":"2018","unstructured":"Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018;55(9):330\u201379.","journal-title":"Curr Probl Surg"},{"issue":"4","key":"2521_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2019.04.007","volume":"2","author":"A Larcher","year":"2019","unstructured":"Larcher A, Wallis CJD, Bex A, et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol. 2019;2(4):365\u201378.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2521_CR7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058\u201366.","journal-title":"Eur Urol"},{"issue":"4","key":"2521_CR8","volume":"2006","author":"S Kumar","year":"2006","unstructured":"Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;2006(4): CD006019.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2521_CR9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O'Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90(12):2317\u201325.","journal-title":"Br J Cancer"},{"issue":"4","key":"2521_CR10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","volume":"76","author":"E Efstathiou","year":"2019","unstructured":"Efstathiou E, Davis JW, Pisters L, et al. Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone. Eur Urol. 2019;76(4):418\u201324.","journal-title":"Eur Urol"},{"issue":"33","key":"2521_CR11","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"ME Taplin","year":"2014","unstructured":"Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705\u201315.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2521_CR12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/oncologie-2024-0242","volume":"26","author":"J Mart\u00edn N\u00fa\u00f1ez","year":"2024","unstructured":"Mart\u00edn N\u00fa\u00f1ez J, Heredia Ciur\u00f3 A, Calvache Mateo A, Ortiz Rubio A, Valenza Pe\u00f1a G, Raya Ben\u00edtez J, Valenza M. Effectiveness of supervised combined aerobic and resistance exercise in fatigue of prostate cancer survivors under androgen deprivation therapy: a systematic review and meta-analysis. Oncologie. 2024;26(6):929\u201339.","journal-title":"Oncologie"},{"issue":"11","key":"2521_CR13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","volume":"37","author":"RR McKay","year":"2019","unstructured":"McKay RR, Ye H, Xie W, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase ii trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol. 2019;37(11):923\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2521_CR14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","volume":"206","author":"RR McKay","year":"2021","unstructured":"McKay RR, Xie W, Ye H, et al. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol. 2021;206(1):80\u20137.","journal-title":"J Urol"},{"issue":"2","key":"2521_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2521_CR16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263\u201382.","journal-title":"Eur Urol"},{"issue":"3","key":"2521_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jncc.2024.05.005","volume":"4","author":"D Zhao","year":"2024","unstructured":"Zhao D, Wang A, Li Y, Cai X, Zhao J, Zhang T, Zhao Y, Dong Y, Zhou F, Li Y, Wang J. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. J Natl Cancer Center. 2024;4(3):280\u20137.","journal-title":"J Natl Cancer Center"},{"issue":"6","key":"2521_CR18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2018.07.006","volume":"74","author":"F Preisser","year":"2018","unstructured":"Preisser F, Mazzone E, Nazzani S, et al. Comparison of perioperative outcomes between cytoreductive radical prostatectomy and radical prostatectomy for nonmetastatic prostate cancer. Eur Urol. 2018;74(6):693\u20136.","journal-title":"Eur Urol"},{"issue":"1","key":"2521_CR19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2017.03.020","volume":"72","author":"SR Leyh-Bannurah","year":"2017","unstructured":"Leyh-Bannurah SR, Gazdovich S, Bud\u00e4us L, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72(1):118\u201324.","journal-title":"Eur Urol"},{"issue":"5","key":"2521_CR20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","volume":"77","author":"L Moris","year":"2020","unstructured":"Moris L, Cumberbatch MG, Van den Broeck T, et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur Urol. 2020;77(5):614\u201327.","journal-title":"Eur Urol"},{"issue":"3","key":"2521_CR21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","volume":"193","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832\u20138.","journal-title":"J Urol"},{"issue":"1","key":"2521_CR22","doi-asserted-by":"crossref","first-page":"BSR20171379","DOI":"10.1042\/BSR20171379","volume":"38","author":"Y Wang","year":"2018","unstructured":"Wang Y, Qin Z, Wang Y, et al. The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis. Biosci Rep. 2018;38(1):BSR20171379.","journal-title":"Biosci Rep"},{"key":"2521_CR23","volume":"375","author":"F Conforti","year":"2021","unstructured":"Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375: e066381.","journal-title":"BMJ"},{"issue":"S4","key":"2521_CR24","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2020.08.116","volume":"31","author":"NA Waser","year":"2020","unstructured":"Waser NA, Adam A, Schweikert B, et al. 1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): systematic literature review and meta-analysis. Ann Oncol. 2020;31(S4):S806.","journal-title":"Ann Oncol"},{"issue":"2","key":"2521_CR25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.32604\/biocell.2023.023750","volume":"47","author":"Z Lu","year":"2023","unstructured":"Lu Z, Tang F, Zhou H, Lu Z, Cai W, Zhang J, et al. Prognostic model for prostate cancer based on glycolysis-related genes and non-negative matrix factorization analysis. Biocell. 2023;47(2):339\u201350.","journal-title":"Biocell"},{"issue":"1","key":"2521_CR26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/pcan.2016.59","volume":"20","author":"RJ Hendriks","year":"2017","unstructured":"Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostat Dis. 2017;20(1):12\u20139.","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"1","key":"2521_CR27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.critrevonc.2012.05.003","volume":"85","author":"PD Grivas","year":"2013","unstructured":"Grivas PD, Robins DM, Hussain M. Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol. 2013;85(1):82\u201393.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2521_CR28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.12688\/f1000research.14026.1","volume":"7","author":"A Afriansyah","year":"2018","unstructured":"Afriansyah A, Hamid ARAH, Mochtar CA, Umbas R. Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis. F1000Res. 2018;7:246.","journal-title":"F1000Res"},{"issue":"2","key":"2521_CR29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/1008-682X.179159","volume":"19","author":"A Mizokami","year":"2017","unstructured":"Mizokami A, Izumi K, Konaka H, et al. Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. Asian J Androl. 2017;19(2):143\u20138.","journal-title":"Asian J Androl"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02521-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:39:17Z","timestamp":1743827957000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02521-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02521-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board authorized this study (approval No. XYFY2021-KL325-01). All of the patients provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}